Drug Profile
Research programme: IL-22RA monoclonal antibody - Merck Serono
Alternative Names: Interleukin 22 subunit alpha receptor - ZymoGenetics; Psoriasis therapy - ZymoGeneticsLatest Information Update: 05 Sep 2014
Price :
$50
*
At a glance
- Originator ZymoGenetics
- Developer Merck Serono
- Class Monoclonal antibodies; Proteins
- Mechanism of Action Interleukin 20 receptor antagonists; Interleukin 22 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 13 Oct 2010 ZymoGenetics has been acquired by Bristol-Myers Squibb
- 08 Sep 2010 Bristol-Myers Squibb agrees to acquire ZymoGenetics ,
- 25 Mar 2009 Preclinical development is ongoing in USA